Skip to content
Screener

Ardelyx ARDX Common Stock Shares Issued

Common Stock Shares Issued at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
373.5M+1.1%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
100.6M+1.6%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
132.9M+0.2%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
75.8M+2.1%
Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
82.5M+27.1%

Other financials

Income statement

See full
Revenue$120.9M+23.8%
Gross profit$115.1M+35.0%
Operating income-$12.4M+13.7%
Net income-$16.7M+12.4%
EPS (diluted)-$0.07+12.5%

Balance sheet

See full
Cash & equivalents$97.2M+7.9%
Total debt$256.2M+24.0%
Total equity$149.0M+6.8%
Total assets$575.9M+23.4%

Cash flow

See full
Operating cash flow-$6.4M+74.7%
CapEx$13.0K-98.0%
Free cash flow-$6.4M+75.3%

Valuation

See full
Market cap$996.75M-23.4%
Enterprise value$1.16B-18.5%
P/S2.2×-1.2×

Profitability

See full
Gross margin94.4%+9.6pp
Operating margin-25.4%
Net margin-12.4%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.7×+0.2×
Current ratio3.3×-1.0×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The source filing: Ardelyx’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437402-26-000044
Line itemJune 30, 2026December 31, 2025
Total liabilities426,881334,655
Commitments and contingencies (Note 14)
Stockholders’ equity
Common stock, $0.0001 par value per share; 500,000,000 shares authorized; 249,147,061 and 244,351,501 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively2524
Additional paid-in capital1,150,4461,113,666
Accumulated deficit(1,001,265)(946,939)
Accumulated other comprehensive (loss) income(193)198
Total stockholders’ equity149,013166,949

Item 1. Financial Statements (Unaudited)

FAQ

What is Ardelyx's common stock shares issued?
Ardelyx (ARDX) reported common stock shares issued of 249.1M in Q2 2026.
How has Ardelyx's common stock shares issued changed year-over-year?
Ardelyx's common stock shares issued increased by 3.5% year-over-year, from 240.8M to 249.1M.
What is the long-term trend for Ardelyx's common stock shares issued?
Over 5 years (2020 to 2025), Ardelyx's common stock shares issued has grown at a 21.2% compound annual growth rate (CAGR), from 93.6M to 244.4M.
What does common stock shares issued mean?
The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.

Ask your AI about Ardelyx's common stock shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude